Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
Hs 578T	XL147	1		flat	flat	Hs578T pilaralisib 1	8	2.013	Inf	0.967	0.00411	0.0	0.967	0.01	0.193	0.525	0.991	Inf	0.967	0.996	0.0	0.967	0.01	0.196	0.519	0.991
Hs 578T	XL147	3		flat	flat	Hs578T pilaralisib 3	8	2.879	Inf	0.971	-0.00618	0.0	0.971	0.01	0.331	0.299	1.0	Inf	0.959	1.01	0.0	0.959	0.01	0.319	0.315	1.0
HCC38	XL147	1	72	flat	flat	HCC38 pilaralisib 0 1 72	8	1.752	Inf	0.949	0.0257	0.0	0.949	0.01	-0.0703	1.0	0.973	Inf	0.955	0.978	0.0	0.955	0.01	-0.0701	1.0	0.977
HCC38	TGX221	1	72	sigmoid	sigmoid	HCC38 TGX-221 0 1 72	8	1.724	Inf	0.938	0.0116	0.289	0.941	5.0	0.676	0.0342	NA	Inf	0.947	0.99	0.289	0.949	5.0	0.672	0.0354	NA
BT-549	XL147	1	72	flat	flat	BT549 pilaralisib 0 1 72	8	1.855	Inf	0.941	0.0385	0.0	0.941	0.01	-0.0931	1.0	0.954	Inf	0.946	0.965	0.0	0.946	0.01	-0.0808	1.0	0.958
HCC38	XL147	3	72	sigmoid	sigmoid	HCC38 pilaralisib 0 3 72	8	1.420	Inf	0.909	0.0219	0.114	0.921	5.0	0.815	0.00631	NA	Inf	0.936	0.985	0.114	0.945	5.0	0.813	0.00654	NA
HCC38	KIN001-244	2	72	flat	flat	HCC38 KIN001-244 0 2 72	8	2.210	Inf	0.948	0.0304	0.0	0.948	0.01	-0.0213	1.0	0.969	Inf	0.944	0.967	0.0	0.944	0.01	-0.0218	1.0	0.966
BT-549	XL147	3	72	flat	flat	BT549 pilaralisib 0 3 72	8	1.772	Inf	0.933	0.0351	0.0	0.933	0.01	-0.0699	1.0	0.962	Inf	0.941	0.969	0.0	0.941	0.01	-0.0712	1.0	0.967
HCC38	XL147	2	72	flat	flat	HCC38 pilaralisib 0 2 72	8	2.194	Inf	0.938	0.0288	0.0	0.938	0.01	-0.0925	1.0	0.968	Inf	0.933	0.969	0.0	0.933	0.01	-0.0418	1.0	0.965
BT-549	MK2206	2	72	sigmoid	sigmoid	BT549 MK-2206 0 2 72	8	1.871	Inf	0.926	0.0188	0.107	0.926	5.0	0.816	0.00627	NA	Inf	0.932	0.983	0.107	0.931	5.0	0.809	0.00694	NA
HCC70	KIN001-244	1	72	flat	flat	HCC70 KIN001-244 0 1 72	8	1.350	Inf	0.889	0.00722	0.0	0.889	0.01	0.616	0.0568	0.988	Inf	0.926	0.995	0.0	0.926	0.01	0.612	0.0584	0.992
HCC38	CAL-101	1	72	sigmoid	sigmoid	HCC38 idelalisib 0 1 72	8	1.723	Inf	0.92	0.00328	1.18	0.903	1.47	0.768	0.0125	NA	Inf	0.932	0.997	1.16	0.918	1.48	0.763	0.0133	NA
HCC70	KIN001-244	2	72	flat	flat	HCC70 KIN001-244 0 2 72	8	1.684	Inf	0.898	-0.0201	0.0	0.898	0.01	0.508	0.119	1.01	Inf	0.916	1.02	0.0	0.916	0.01	-0.0458	1.0	1.01
BT-549	AS605240	2	72	flat	flat	BT549 AS-605240 0 2 72	8	1.961	Inf	0.91	0.0479	0.0	0.91	0.01	0.414	0.201	0.949	Inf	0.914	0.954	0.0	0.914	0.01	0.418	0.197	0.951
BT-20	KIN001-244	1	72	flat	flat	BT20 KIN001-244 0 1 72	8	2.125	Inf	0.911	0.0401	0.0	0.911	0.01	-0.00641	1.0	0.957	Inf	0.908	0.958	0.0	0.908	0.01	-0.00745	1.0	0.955
HCC70	KIN001-244	3	72	flat	flat	HCC70 KIN001-244 0 3 72	8	2.472	Inf	0.916	0.0295	0.0	0.916	0.01	-0.0208	1.0	0.969	Inf	0.899	0.965	0.0	0.899	0.01	-0.00883	1.0	0.963
BT-20	CAL-101	3	72	flat	flat	BT20 idelalisib 0 3 72	8	2.589	Inf	0.916	0.0535	0.0	0.916	0.01	0.0547	0.845	0.944	Inf	0.894	0.932	0.0	0.894	0.01	0.0506	0.856	0.929
HCC1806	Alpelisib	1	72	flat	flat	HCC1806 alpelisib 0 1 72	8	2.771	Inf	0.918	0.0583	0.0	0.918	0.01	-0.337	1.0	0.94	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC38	KIN001-244	3	72	flat	flat	HCC38 KIN001-244 0 3 72	8	1.472	Inf	0.849	0.0658	0.0	0.849	0.01	0.182	0.548	0.929	Inf	0.891	0.952	0.0	0.891	0.01	0.181	0.549	0.948
HCC1806	Alpelisib	3	72	flat	flat	HCC1806 alpelisib 0 3 72	8	3.224	Inf	0.93	0.0502	0.0	0.93	0.01	-0.335	1.0	0.948	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC1806	Alpelisib	2	72	flat	flat	HCC1806 alpelisib 0 2 72	8	2.856	Inf	0.921	0.0566	0.0	0.921	0.01	-0.336	1.0	0.941	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919
HCC1806	AS605240	2	72	sigmoid	sigmoid	HCC1806 AS-605240 0 2 72	8	2.813	Inf	0.913	0.0124	0.569	0.913	2.8	0.936	0.000261	NA	Inf	0.883	0.983	0.559	0.882	2.81	0.931	0.000333	NA
HCC1806	AS605240	1	72	sigmoid	sigmoid	HCC1806 AS-605240 0 1 72	8	2.728	Inf	0.911	0.0128	0.569	0.91	2.8	0.936	0.000262	NA	Inf	0.883	0.983	0.559	0.882	2.81	0.931	0.000333	NA
HCC1806	AS605240	3	72	sigmoid	sigmoid	HCC1806 AS-605240 0 3 72	8	3.181	Inf	0.923	0.011	0.57	0.923	2.81	0.936	0.000257	NA	Inf	0.883	0.983	0.559	0.882	2.81	0.931	0.000333	NA
HCC38	AZD-6482	3	72	sigmoid	sigmoid	HCC38 AZD6482 0 3 72	8	1.420	Inf	0.821	0.0615	0.324	0.826	5.0	0.849	0.00342	NA	Inf	0.875	0.957	0.323	0.879	5.0	0.846	0.00367	NA

|<
<<
Previous
Page 2 of 18
Next
>>
>
26 to 50 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)